^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Alkylating agent

    Related drugs:
    Apply
    SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma (NCT03138161)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    04/13/2017
    Primary completion :
    12/31/2030
    Completion :
    07/31/2031
    PD-L1 • PD-1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Yondelis (trabectedin)
    Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies (NCT04959175)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/23/2021
    Primary completion :
    04/27/2027
    Completion :
    04/30/2027
    EGFR • IGH
    |
    cyclophosphamide • sirolimus • fludarabine IV • Neupogen (filgrastim)
    NeoTIL in Advanced Solid Tumors (NCT04643574)
    Phase 1
    Centre Hospitalier Universitaire Vaudois
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    03/09/2021
    Primary completion :
    11/01/2027
    Completion :
    11/01/2027
    TNFA • IL2
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
    Lurbinectedin in FET-Fused Tumors (LiFFT) (NCT05918640)
    Phase 1/2
    Children's Hospital of Philadelphia
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/27/2023
    Primary completion :
    07/30/2026
    Completion :
    07/30/2028
    EWSR1 • ETV1 • FLI1 • FUS • TAF15 • ETV4
    |
    Zepzelca (lurbinectedin)
    Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors (NCT06825455)
    Phase 1
    Peking University
    Not yet recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/01/2025
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    CD276
    |
    cyclophosphamide • fludarabine IV
    Optimizing PTCy Dose and Timing (NCT03983850)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/09/2019
    Primary completion :
    05/31/2025
    Completion :
    05/29/2026
    KRAS • PTEN • IGH • FBXW7
    |
    KRAS mutation • RAS mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV • busulfan • cyclophosphamide intravenous
    Fluoroquinolone Resistance Prevalence Study (FRE) (NCT05824689)
    Phase N/A
    Hackensack Meridian Health
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    07/08/2022
    Primary completion :
    12/17/2024
    Completion :
    04/01/2025
    CD34
    |
    melphalan
    Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (NCT04965597)
    Phase 2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    04/19/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C
    |
    LDH elevation
    |
    methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV
    Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCI-2017-01311) (NCT03246906)
    Phase 2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/11/2017
    Primary completion :
    05/03/2025
    Completion :
    05/03/2025
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous
    Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT04994808)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/11/2023
    Primary completion :
    10/03/2026
    Completion :
    04/03/2027
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)
    Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy (NCT06478862)
    Phase 2
    Lipomedix Pharmaceuticals Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    06/13/2024
    Primary completion :
    06/01/2026
    Completion :
    01/01/2027
    BRCA
    |
    Promitil (pegylated liposomal mitomycin-c prodrug)
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/30/2018
    Primary completion :
    06/10/2025
    Completion :
    06/10/2026
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (NCT06013423)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    07/23/2024
    Primary completion :
    10/31/2031
    Completion :
    10/31/2032
    KMT2A • HLA-DRB1 • HLA-B
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
    Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (FIORELLA) (NCT03495960)
    Phase 2
    International Extranodal Lymphoma Study Group (...
    Completed
    Last update posted :
    01/30/2025
    Initiation :
    06/15/2019
    Primary completion :
    12/12/2024
    Completion :
    12/12/2024
    CD20
    |
    Rituxan (rituximab) • lenalidomide • temozolomide • Matulane (procarbazine hydrochloride)
    International PPB/DICER1 Registry (NCT03382158)
    Phase N/A
    Children's Hospitals and Clinics of Minnesota
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/06/2016
    Primary completion :
    12/06/2030
    Completion :
    12/06/2035
    DICER1
    |
    doxorubicin hydrochloride • cyclophosphamide
    Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial (NCT06042569)
    Phase 2
    City of Hope Medical Center
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/16/2024
    Primary completion :
    03/20/2028
    Completion :
    03/20/2028
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    docetaxel • cyclophosphamide
    CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (CNS-PHLAT) (NCT06687772)
    Phase 2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    01/16/2025
    Primary completion :
    07/31/2027
    Completion :
    07/31/2029
    CD34
    |
    carmustine • melphalan • thiotepa
    KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (NCT06767046)
    Phase 1
    Corregene Biotechnology Co., Ltd
    Not yet recruiting
    Last update posted :
    01/09/2025
    Initiation :
    01/10/2025
    Primary completion :
    11/30/2028
    Completion :
    12/31/2028
    KRAS
    |
    cyclophosphamide • fludarabine IV
    Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2) (NCT03838744)
    Phase 2
    Italian Sarcoma Group
    Completed
    Last update posted :
    12/04/2024
    Initiation :
    05/20/2020
    Primary completion :
    11/29/2024
    Completion :
    11/29/2024
    BRCA1 • BRCA2 • BRCA
    |
    Lynparza (olaparib) • Yondelis (trabectedin)
    Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma (NCT06245629)
    Phase N/A
    Uppsala University
    Recruiting
    Last update posted :
    11/28/2024
    Initiation :
    11/24/2024
    Primary completion :
    03/31/2025
    Completion :
    11/30/2025
    SLC1A5
    |
    bortezomib • bendamustine • melphalan
    Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors (NCT06500819)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    10/31/2024
    Initiation :
    07/11/2024
    Primary completion :
    07/01/2029
    Completion :
    07/01/2029
    CD276
    |
    cyclophosphamide
    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (NCT02977780)
    Phase 2
    Patrick Wen, MD
    Recruiting
    Last update posted :
    10/17/2024
    Initiation :
    02/09/2017
    Primary completion :
    02/01/2027
    Completion :
    04/30/2027
    IDH1
    |
    IDH1 R132
    |
    temozolomide • Nerlynx (neratinib) • Verzenio (abemaciclib) • CC-115 • QBS72S
    RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors (NCT06545201)
    Phase 1
    Henan Cancer Hospital
    Not yet recruiting
    Last update posted :
    08/09/2024
    Initiation :
    08/01/2024
    Primary completion :
    04/01/2026
    Completion :
    04/01/2027
    KRAS
    |
    cyclophosphamide • fludarabine IV
    RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors (NCT06546150)
    Phase 1
    Henan Cancer Hospital
    Not yet recruiting
    Last update posted :
    08/09/2024
    Initiation :
    08/01/2024
    Primary completion :
    04/01/2026
    Completion :
    04/01/2027
    KRAS
    |
    cyclophosphamide • fludarabine IV
    Nivolumab for Recurrent or Progressive IDH Mutant Gliomas (NCT03557359)
    Phase 2
    Fabio Iwamoto, MD
    Active, not recruiting
    Last update posted :
    07/18/2024
    Initiation :
    06/12/2018
    Primary completion :
    06/01/2025
    Completion :
    12/01/2026
    IDH1 • IDH2
    |
    IDH1 R132H • IDH1 R132
    |
    Opdivo (nivolumab)
    Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773)
    Phase 1
    University of Arizona
    Active, not recruiting
    Last update posted :
    07/11/2024
    Initiation :
    11/29/2016
    Primary completion :
    08/25/2025
    Completion :
    08/25/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    cyclophosphamide • bendamustine • cyclophosphamide intravenous
    Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM (SONOBIRD) (NCT05902169)
    Phase 3
    CarThera
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    01/29/2024
    Primary completion :
    01/28/2028
    Completion :
    06/30/2028
    BRAF • IDH1
    |
    BRAF mutation • IDH1 R132H • IDH1 R132
    |
    carboplatin • temozolomide • lomustine
    Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL (NCT05114837)
    Phase 1/2
    Masonic Cancer Center, University of Minnesota
    Not yet recruiting
    Last update posted :
    06/12/2024
    Initiation :
    09/01/2024
    Primary completion :
    08/01/2028
    Completion :
    08/01/2028
    CD19
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV
    Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis (NCT06022939)
    Phase 3
    SWOG Cancer Research Network
    Not yet recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/01/2024
    Primary completion :
    07/29/2030
    Completion :
    10/29/2030
    CD34
    |
    Chr t(11;14)
    |
    bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection
    HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE) (NCT06001385)
    Phase 2
    Center for International Blood and Marrow Trans...
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/08/2023
    Primary completion :
    02/01/2026
    Completion :
    06/30/2026
    HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE) (NCT05572476)
    Phase 2
    Institut Bergonié
    Withdrawn
    Last update posted :
    06/05/2024
    Initiation :
    10/01/2023
    Primary completion :
    05/31/2024
    Completion :
    05/31/2024
    PD-L1
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV • Zepzelca (lurbinectedin)
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (NCT05436418)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    11/18/2022
    Primary completion :
    06/25/2027
    Completion :
    07/02/2027
    IGH • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (NCI-2019-03188) (NCT03970096)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    11/19/2019
    Primary completion :
    12/31/2026
    Completion :
    12/31/2028
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cyclophosphamide • sirolimus • fludarabine IV • thiotepa • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous • methotrexate IV
    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma (NCT01163357)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/28/2011
    Primary completion :
    07/20/2019
    Completion :
    12/31/2024
    HLA-DRB1
    |
    Chr del(17p)
    |
    bortezomib • sirolimus • melphalan • fludarabine IV
    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCI-2017-01069) (NCT03192397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/09/2017
    Primary completion :
    08/21/2023
    Completion :
    05/21/2027
    HLA-DRB1
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous
    HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS) (NCT04904588)
    Phase 2
    Center for International Blood and Marrow Trans...
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    09/30/2021
    Primary completion :
    07/01/2024
    Completion :
    07/01/2024
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    01/25/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    HLA-DRB1
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous
    Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors (NCT05693844)
    Phase 1/2
    Chinese PLA General Hospital
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    01/20/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    MSLN
    |
    MSLN expression
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • CD40 ligand expressing MSLN-CAR T
    Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (NCT04942730)
    Phase 2
    St. Petersburg State Pavlov Medical University
    Completed
    Last update posted :
    05/07/2024
    Initiation :
    01/21/2021
    Primary completion :
    04/30/2024
    Completion :
    04/30/2024
    HLA-DRB1 • HLA-DQB1 • HLA-B
    |
    cyclophosphamide • bendamustine • fludarabine IV • busulfan • cyclophosphamide intravenous
    Allo HSCT Using RIC and PTCy for Hematological Diseases (NCT05805605)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    05/01/2023
    Primary completion :
    10/22/2027
    Completion :
    10/22/2028
    NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
    |
    cyclophosphamide • sirolimus • fludarabine IV
    Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers (NCT01597219)
    Phase 2
    University College, London
    Completed
    Last update posted :
    05/03/2024
    Initiation :
    03/01/2013
    Primary completion :
    01/01/2024
    Completion :
    01/01/2024
    HLA-DRB1 • HLA-DQB1 • HLA-B
    |
    cyclophosphamide • fludarabine IV